Kaplan-Meier survival curves for 5-year overall survival (OS) in the Cross-Border Neuro-Oncology Program. (A) Five-year OS (2010-2017): All CNS tumors (CNSTs), 52%; medulloblastoma, 40%; ependymoma, 44%; low-grade glioma, 91%; craniopharyngioma, 75%; other, 25%. (B) Three-year overall survival by Era (Era 1: 2010-2013; Era 2: 2014-2017). Era 1 3-year OS: 37%; Era 2 3-year OS: 53% (P = .23). Three-year OS (2010-2017): All CNSTs, 60%; medulloblastoma, 55%; ependymoma, 67%; low-grade glioma, 91%; craniopharyngioma, 75%; other, 25%.